| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
BVF Partners L.P.
|
16.001m | 19.14% | -3.750m | Mar 31 2026 |
| 2 |
Deep Track Capital LP
|
6.409m | 7.67% | +1.799m | Mar 31 2026 |
| 3 |
Cormorant Asset Management, LP
INSIDER
|
4.480m | 5.36% | +125.000k | Mar 31 2026 |
| 4 |
Janus Henderson Investors
|
3.452m | 4.13% | +1.356m | Mar 31 2026 |
| 5 |
Reich (Kristian)
|
3.010m | 3.60% | +48.978k | Apr 01 2026 |
|
1
BVF Partners L.P.
|
19.14%
16.001m
|
|
2
Deep Track Capital LP
|
7.67%
6.409m
|
|
3
Cormorant Asset Management, LP
INSIDER
|
5.36%
4.480m
|
|
4
Janus Henderson Investors
|
4.13%
3.452m
|
|
5
Reich (Kristian)
|
3.60%
3.010m
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 39.89% of Moonlake Immunotherapeutics, with BVF Partners L.P. the biggest at 19.14%, followed by Deep Track Capital LP (7.67%) and Cormorant Asset Management, LP (5.36%). |
| Date | Insider & Role | Type | Price | Quantity | Volume |
|---|---|---|---|---|---|
| Oct 26 2026 |
John Mitchell
CEO
|
Purchases
|
$182.45 | + 15,000 | $2,736,750 |
| Oct 23 2026 |
Sarah Chen
CFO
|
Sales
|
$179.80 | - 8,500 | $1,528,300 |
| Oct 19 2026 |
Robert Williams
COO
|
Purchases
|
$175.20 | + 12,000 | $2,102,400 |
| Oct 14 2026 |
Emily Rodriguez
Director
|
Sales
|
$181.30 | - 5,200 | $942,760 |
| Oct 08 2026 |
Michael Thompson
SVP Operations
|
Purchases
|
$170.50 | + 20,000 | $3,410,000 |
| Oct 01 2026 |
Lisa Park
General Counsel
|
Sales
|
$177.90 | - 6,800 | $1,209,720 |
| No transactions found for this filter. | |||||
|
John Mitchell
PURCHASES
|
Oct 26 2026
$182.45
|
|
Sarah Chen
SALES
|
Oct 23 2026
$179.80
|
|
Robert Williams
PURCHASES
|
Oct 19 2026
$175.20
|
|
Emily Rodriguez
SALES
|
Oct 14 2026
$181.30
|
|
Michael Thompson
PURCHASES
|
Oct 08 2026
$170.50
|
|
Lisa Park
SALES
|
Oct 01 2026
$177.90
|
| No transactions found for this filter. | |
| Insider transactions show you what executives, directors and major shareholders do with their own stock: people who know the company from the inside. Buys are the most telling signal, because insiders invest their own money. Sells are harder to read, since they can also be driven by taxes, diversification or expiring option programs. |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


